Onkologia - aktualności medyczne dla lekarzy

esmo logo

T-DM1 is active and well tolerated in patients with HER2-positive metastatic breast cancer and brain metastases


The exploratory subgroup analysis of the KAMILLA trial represents the largest reported cohort of patients with HER2-positive metastatic breast cancer and brain metastases treated with T-DM1 in a prospective setting. The study team observed clinically meaningful antitumor activity in patients with and without prior radiotherapy, suggesting that T-DM1 is active, well tolerated in this difficult to treat population and warrants further exploration.

asco logo

Education session to address recent advances in nuclear medicine theranostics for cancer


Theranostics is a rapidly emerging field in nuclear medicine that relies on radiopharmaceuticals for both diagnostics and therapy. In the theranostic paradigm, diagnostic radiopharmaceuticals identify cancer tissues with a specific treatment target through imaging techniques, such as PET scans. In patients whose cancer has the treatment target, therapeutic radiopharmaceuticals then deliver cytotoxic levels of radiation to tumor tissues based on the presence of the target, while sparing the surrounding healthy tissues.

asco logo

Novel strategies aim to tackle EGFR exon 20 insertions in lung cancer


The effort to fight cancer with a targeted approach has been an integral part of oncology practice during the past few years. Currently, EGFR–tyrosine kinase inhibitors (TKIs), such as osimertinib, erlotinib, and gefitinib, comprise the standard of care as frontline options for non–small cell lung cancer (NSCLC) with sensitive mutations in the EGFR gene.

asco logo

Melanoma at ASCO20: shortening, changing, and repurposing therapeutics in patients with unresectable disease


Several studies presented during the ASCO20 Virtual Scientific Program explored unique treatment approaches for advanced and refractory disease, many of which are poised in the near term to become improvements to the standard of care in patients with unresectable melanoma.

esmo logo

FDA approves Pembrolizumab for first-line treatment of MSI-H/dMMR colorectal cancer


On 29 June 2020, the US Food and Drug Administration (FDA) approved pembrolizumab for the first-line treatment of patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer. Approval was based on KEYNOTE‑177 (NCT02563002), a multicentre, international, open-label, active-controlled, randomised trial that enrolled 307 patients with previously untreated unresectable or metastatic MSI-H or dMMR colorectal cancer.

esmo logo

FDA approves Avelumab for urothelial carcinoma maintenance treatment


On 30 June 2020, the US Food and Drug Administration (FDA) approved avelumab for maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma (UC) that has not progressed with first-line platinum-containing chemotherapy. Efficacy of avelumab for maintenance treatment of UC was investigated in the JAVELIN Bladder 100 trial (NCT02603432), a randomised, multicentre, open-label trial that enrolled 700 patients with unresectable, locally advanced or metastatic urothelial carcinoma that had not progressed with four to six cycles of first-line platinum-containing chemotherapy.

asco logo

Expert perspective on ASCO20 gastrointestinal cancers research


Donafenib, a deuterated derivative of sorafenib, was tested against sorafenib in the frontline setting in hepatitis B– associated hepatocellular carcinoma (HCC) in a large, multi-institutional study in China (Abstract 4506). Donafenib was associated with a mild improvement in overall survival (OS) compared with sorafenib in the intention-to-treat population.

asco logo

Expert perspective on ASCO20 immunotherapy research


CAR T-cell therapy with BCMA-targeting idecabtagene-vicleucel (ide-cel) has emerged to be a game-changer as shown by this first pivotal phase II trial of CAR T-cell therapy in multiple myeloma (MM). Ide-cel is a first-in-class BCMA-directed CAR T-cell therapy, with 4-1BB costimulatory domain and CD3Z T-cell activation domain.

esmo logo

FDA approves combination of Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf for HER2-positive breast cancer


On 29 June 2020, the US Food and Drug Administration (FDA) approved a new fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase–zzxf for subcutaneous injection for the following indications. Use in combination with chemotherapy as - neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer.

asco logo

Expert perspective on ASCO20 breast cancer research


Patients with HER2-positive breast cancer have a 50% chance of developing brain metastases, resulting in poor overall survival (OS). Tucatinib is an oral HER2-specific tyrosine kinase inhibitor with activity in combination with capecitabine or trastuzumab in patients with HER2-positive breast cancer with or without brain metastases in original trials.

esmo logo

Outcomes from second-line chemotherapy in patients with cholangiocarcinoma and FGFR2 fusions


Dr Milind Javle of the the University of Texas MD Anderson Cancer Center in Houston, TX, US and colleagues reported at ESMO World Congress on Gastrointestinal Cancer 2020 Virtual (1-4 July) that outcomes from second-line chemotherapy in patients with cholangiocarcinoma and fibroblast growth factor receptor 2 (FGFR2) fusions are similar to those reported in the literature for all patients with cholangiocarcinoma regardless of genomic status and remain dismal.

esmo logo

Maintenance Olaparib in elderly patients with a germline BRCA mutation and metastatic pancreatic cancer


Safety of maintenance olaparib in patients with a germline BRCA1 and/or BRCA2 mutation and metastatic pancreatic cancer is consistent irrespective of age. Furthermore, patients aged ≥65 years can derive long-term progression-free survival (PFS) benefit and durable tumour response from the maintenance treatment according to an additional analysis of the POLO trial.

esmo logo

EMA recommends granting a marketing authorisation for biosimilar Bevacizumab


On 25 June 2020, the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Aybintio (bevacizumab), intended for the treatment of carcinoma of the colon or rectum, breast cancer, non-small cell lung cancer (NSCLC), renal cell cancer (RCC), epithelial ovarian, fallopian tube or primary peritoneal cancer, and carcinoma of the cervix.

esmo logo

FDA approves Pembrolizumab for cutaneous squamous cell carcinoma


On 24 June 2020, the US Food and Drug Administration (FDA) approved pembrolizumab (KEYTRUDA, Merck & Co., Inc.) for patients with recurrent or metastatic cutaneous squamous cell carcinoma (cSCC) that is not curable by surgery or radiation. Efficacy was investigated in KEYNOTE-629 (NCT03284424), a multicentre, multi-cohort, non-randomised, open-label trial.

asco logo

Breast cancer research at ASCO20 Virtual Scientific Program highlights new avenues and better outcomes


The ASCO20 Virtual Scientific Program featured a variety of important and innovative breast cancer research. The following are some of the studies with potential to significantly impact clinical practice and patient outcomes, as selected by ASCO Daily News Expert Panel member Arielle Heeke, MD, of the Levine Cancer Institute.

asco logo

Top lung cancer research presented at the ASCO20 Virtual Scientific Program has implications for clinical practice


Although the ASCO Annual Meeting felt much different this year given the virtual format, the quality of research presented at the meeting was undiminished, particularly in the field of lung cancer. ASCO Daily News Expert Panel member Jared Weiss, MD, of the University of North Carolina School of Medicine, reviewed the most influential lung cancer research presented during the ASCO20 Virtual Scientific Program and provided insights on how the new data will influence clinical practice.

asco logo

New guideline for locally advanced esophageal cancer supports multimodality therapy and multidisciplinary treatment approach


ASCO has released a new guideline for the treatment of locally advanced esophageal cancer that will provide a context for the current standards of care, fill gaps in clinicians’ knowledge of therapy options, and help define future treatment. An Expert Panel developed the guideline based on 17 randomized controlled trials that met the inclusion criteria, and, where possible, data were extracted separately for squamous cell carcinoma and adenocarcinoma.

esmo logo

FDA grants accelerated approval to lurbinectedin for metastatic SCLC


On 15 June 2020, the US Food and Drug Administration (FDA) granted accelerated approval to lurbinectedin (ZEPZELCA, Pharma Mar S.A.) for adult patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy. Efficacy was demonstrated in the PM1183-B-005-14 trial (Study B-005; NCT02454972), a multicentre open-label, multi-cohort study enrolling 105 patients with metastatic SCLC who had disease progression on or after platinum-based chemotherapy.

asco logo

ASCO20 data show clear benefit for total neoadjuvant therapy in rectal cancer


Although total neoadjuvant therapy has become the standard of care at many institutions for rectal cancer, there have not been prospective data showing a clear benefit until now, with results from OPRA, RAPIDO, and PRODIGE 23 presented during ASCO20 Virtual Scientific Program. The results from OPRA, PRODIGE 23, and RAPIDO not only shape the neoadjuvant approach in rectal cancer, but they may also move the approach of watch-and-wait into the mainstream.

Dr Agata Szade laureatka pierwszej edycji grantu naukowego fundacji DKMS

Dla młodych naukowców – grant naukowy fundacji DKMS – druga edycja


Ruszyła druga edycja „Grantu naukowego Fundacji DKMS”. Projekt został uruchomiony w zeszłym roku, w ramach inicjatywy „Program Rozwoju Polskiej Transplantologii i Wsparcia Pacjentów Cierpiących na Nowotwory Krwi”. Grant jest skierowany do młodych naukowców, którzy swoją pracę skupiają wokół transplantologii hematologicznej oraz terapii komórkowych. Został z entuzjazmem przyjęty w środowisku hematologicznym i uzyskał honorowy Patronat PTHiT.

ESMO - logo

FDA approves Brigatinib for ALK-positive metastatic NSCLC


On 22 May 2020, the US Food and Drug Administration approved brigatinib for adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test.

ESMO - logo

Esmo Breast Cancer Virtual Meeting 2020: Results in hormone receptor-positive and tnbc subgroups from the phase III BROCADE3 trial


In the BROCADE3 study conducted in patients with gBRCA-associated advanced breast cancer, the addition of veliparib to carboplatin plus paclitaxel with continuation of veliparib monotherapy at intensified dose and schedule if chemotherapy was withdrawn prior to disease progression led to improved progression-free survival (PFS) in patients with hormone receptor (HR)-positive disease and in patients with triple negative breast cancer (TNBC).

ASCO - logo

Incorporating immunotherapy into the management of unresectable recurrent or metastatic head and neck cancer


Despite the approvals of immunotherapeutic agents in recurrent or metastatic disease (R/M) head and neck squamous cell carcinoma (HNSCC), questions still remain regarding the optimal use of checkpoint inhibitors.

ESMO - logo

FDA approves Atezolizumab for first-line treatment of metastatic NSCLC with high PD-L1 expression


On 18 May 2020, the US Food and Drug Administration approved atezolizumab for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have high PD-L1 expression (PD-L1 stained ≥ 50% of tumour cells [TC ≥ 50%] or PD-L1 stained tumour-infiltrating immune cells [IC] covering ≥ 10% of the tumour area [IC ≥ 10%]), with no EGFR or ALK genomic tumour aberrations.

ESMO - logo

FDA approves Nivolumab plus Ipilimumab for first-line metastatic NSCLC with PD-L1 tumour expression ≥1%


On 15 May 2020, the US Food and Drug Administration approved the combination of nivolumab plus ipilimumab as first-line treatment for patients with metastatic non-small cell lung cancer (NSCLC) whose tumours express PD-L1 ≥1%, as determined by an FDA-approved test, with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumour aberrations.

ESMO - logo

ESMO Breast Cancer Virtual Meeting 2020: Results of an interim analysis of the PHranceSCa study


Patients with HER2-positive early breast cancer prefer a subcutaneous fixed-dose combination of pertuzumab and trastuzumab over intravenous treatment.

ESMO - logo

ESMO Breast Cancer Virtual Meeting 2020: Final results of the LOTUS study


Final analysis of the LOTUS trial, after deaths in 70% of study population, shows numerically longer overall survival (OS) with ipatasertib plus paclitaxel versus placebo plus paclitaxel in patients with inoperable locally advanced/metastatic triple-negative breast cancer (TNBC).

ASCO - logo

New cancer cachexia guideline addresses common quality-of-life issue


ASCO recently released a new evidence-based guideline regarding the clinical management of cancer cachexia in adult patients with advanced cancer.1 The guideline is the result of a literature review that included 20 systematic reviews and 13 randomized clinical trials.

ESMO - logo

FDA approves Olaparib for HRR gene-mutated metastatic castration resistant prostate cancer


On 19 May 2020, the US Food and Drug Administration approved olaparib for adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.

baner Virtual Medical Masterclass – Rak piersi

Bezpłatny cykl: Virtual Medical Masterclass – Rak piersi


Od maja ruszyły zapisy do udziału w bezpłatnym cyklu Virtual Medical Masterclass – Rak Piersi. Cykl wydarzeń online skierowany jest przede wszystkich do onkologów, chirurgów onkologicznych, radioterapeutów oraz lekarzy innych specjalizacji zaangażowanych w leczenie chorych na raka piersi.

ESMO - logo

FDA approves Ripretinib for advanced gastrointestinal stromal tumour


On 15 May 2020, FDA approved ripretinib, for adult patients with advanced gastrointestinal stromal tumour (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib.

ASCO - logo

The role of lymphadenectomy in muscle-invasive bladder cancer


A multitude of studies have tested the effect of a more extensive pelvic lymph node dissection (PLND) during radical cystectomy (RC) aiming to achieve a prolonged recurrence-free and overall survival from the surgical treatment.

ASCO - logo

Patients with mCRPC have better HRQoL when treated with Olaparib


Men with metastatic castration-resistant prostate cancer (mCRPC) who had disease progression while receiving enzalutamide or abiraterone and who had homologous recombination repair (HRR) gene alterations demonstrated longer progression-free survival and better measures of response when treated with olaparib than enzalutamide or abiraterone.

ESMO - logo

Atezolizumab combined with Bevacizumab in unresectable HCC


In patients with unresectable hepatocellular carcinoma (HCC) included in the IMbrave150 study, the combination of atezolizumab and bevacizumab was associated with better progression-free survival (PFS) and overall survival (OS) outcomes, response rate and preservation of quality of life (QoL) than a treatment with sorafenib.

ESMO - logo

FDA grants accelerated approval to Rucaparib for BRCA-mutated metastatic castration-resistant prostate cancer


On 15 May 2020, FDA granted accelerated approval to rucaparib for patients with deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy.

baner aktualności medyczne

Wspólne wytyczne TChP i PTChO dla udzielania akredytacji Towarzystw dla ośrodków wykonujących zabiegi cytoredukcyjne oraz procedury HIPEC


W następstwie dyskusji związanej z potrzebą oceny jakości i wyników leczenia, na wniosek Sekcji Nowotworów Otrzewnej Polskiego Towarzystwa Chirurgii Onkologicznej opracowano warunki akredytacji i powołano Komisję Akredytacyjną dla ośrodków wykonujących zabiegi cytoredukcyjne i HIPEC w leczeniu pierwotnych i wtórnych nowotworów otrzewnej. Źródło: Towarzystwo Chirurgów Polskich

Metody leczenia wczesnego raka piersi – dziś i jutro - baner

Webinar: Metody leczenia wczesnego raka piersi – dziś i jutro


Webinar ma celu uporządkowanie wiedzy i przedstawienie algorytmów terapeutycznych w kontekście perspektyw leczenia wczesnego raka piersi. Podczas webinarium dr n. med. Agnieszka Jagiełło-Gruszfeld omówi tematy dotyczące obecnych metod leczenia wczesnego raka piersi jak i perspektyw, w tym najnowszych badań i produktów leczniczych będących w trakcie procesu refundacyjnego. Nie zabraknie również doniesień z ostatnich zagranicznych konferencji naukowych.

ASCO - logo

NK cells emerge as potentially useful targets for extending survival in triple-negative breast cancer


Triple-negative breast cancer (TNBC) is a highly aggressive disease that is resistant to endocrine therapy and anti-HER2 molecular targeted treatments. However, results from a new study suggest that natural killer (NK) cells may be an effective alternative focus for future immune-based treatments to improve survival in patients with TNBC.

ASCO - logo

Vitamin D reduces incidence of advanced cancers in normal-weight individuals


Vitamin D supplementation reduced the incidence of advanced cancer in a large study of older adults (men ≥ 50 years old, women ≥ 55 years old), with adults of normal body mass index (BMI) deriving the most benefit.

ESMO - logo

FDA approves Olaparib plus Bevacizumab as maintenance treatment for ovarian cancer


On 8 May 2020, the US Food and Drug Administration (FDA) expanded the indication of olaparib (LYNPARZA, AstraZeneca Pharmaceuticals, LP) to include its combination with bevacizumab for first-line maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer

ASCO - logo

Study reveals association between immune cell profiles and functional decline in women with breast cancer receiving chemotherapy


Higher prechemotherapy lymphocytes and lower neutrophil:lymphocyte ratio (NLR) were found to correlate with an increased risk of functional decline and reduced ability to regain baseline physical function in women with breast cancer in a recent study from the University of Rochester.

ESMO - logo

FDA approves Selpercatinib for lung and thyroid cancers with RET gene mutations or fusions


On 8 May 2020, the US Food and Drug Administration (FDA) granted accelerated approval to Selpercatinib for the following indications: adult patients with metastatic RET fusion-positive non-small cell lung cancer, adult and paediatric patients ≥ 12 years of age with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy.

ESMO - logo

EMA Does Not Recommend Extending the Use of Pembrolizumab


On 30 April 2020, the European Medicines Agency (EMA) announced that it has finalised its assessment of an application for the use of pembrolizumab (Keytruda) alone as a first-line treatment in patients with non-small cell lung cancer (NSCLC) and low levels of the protein PD-L1.

ESMO - logo

EMA recommends extension of indications for Encorafenib


On 30 April 2020, the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Encorafenib.

ASCO - logo

The current treatment paradigm of early-stage HPV-related oropharynx cancer


Head and neck squamous cell carcinoma (HNSCC) is a major cause of cancer morbidity and mortality worldwide. It is the sixth most common cancer globally and attributed to 300,000 deaths each year.1 However, over the past decade evidence has proved that HNSCC is not a monolithic disease, and tumors driven by HPV represent a clear and distinct subset of HNSCC.

ESMO - logo

FDA approves Niraparib for first-line maintenance treatment of advanced ovarian cancer


On 29 April 2020, the US Food and Drug Administration (FDA) approved Niraparib for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy.

ESMO - logo

FDA approves new dosing regimen for pembrolizumab


On 28 April 2020, the US Food and Drug Administration (FDA) granted accelerated approval to a new dosing regimen of 400 mg every six weeks for pembrolizumab across all currently approved adult indications, in addition to the current 200 mg every three weeks dosing regimen.

ASCO - logo

Using immune checkpoint inhibition for head and neck cancer in the curative setting


Restoring the anti-tumoral immune response is an important cancer treatment strategy. The most effective means to do this to date has been interruption of immune tolerance signaling through the PD-1/PD-L1 pathway. Such immune checkpoint inhibition through the PD-1 targeting antibodies, pembrolizumab and nivolumab, has reproducible activity in head and neck cancer, and impacts survival in the first-line metastatic and cisplatin-refractory settings.

ESMO - logo

Kinase fusions in ESR1 wild-type metastatic breast cancer


Results of the study published on 26 April 2020 in the Annals of Oncology show that kinase fusions are enriched in ESR1 wild-type metastatic breast cancer after progression on endocrine therapy. The authors emphasised that fusion testing of metastatic breast cancers upon progression to endocrine therapy may provide new therapeutic options in this setting.

ESMO - logo

Mortality among thoracic cancer patients with COVID-19 is unexpectedly high


The data, presented today at the American Association for Cancer Research (AACR) Virtual Annual Meeting by Dr Marina Chiara Garassino from Fondazione IRCCS Istituto Nazionale Tumori in Milan, Italy, includes the results for the first 200 patients enrolled in the registry up to 12 April 2020, and represents the first large dataset for patients with thoracic cancers infected with COVID-19.

ESMO - logo

First report on the prognosis of COVID-19 patients with cancer in the US


A group of clinicians from the Department of Medicine, Icahn School of Medicine at Mount Sinai, Mount Sinai Beth Israel, New York, NY, US sought to determine if cancer patients with COVID-19 in the US have a poorer prognosis. In an article published in the Annals of Oncology, they analysed the electronic medical records of Mount Sinai Health System in New York City and found 334 patients (6%) with cancer among 5,688 patients diagnosed with COVID-19.

ASCO - logo

Long-term outcomes and responses to retreatment in patients with Melanoma treated with PD-1 blockade


We retrospectively analyzed all patients with nonuveal, unresectable stage III/IV melanoma treated with single-agent anti–PD-1 therapy at Memorial Sloan Kettering from 2009-2018 who had discontinued treatment and had at least 3 months of follow-up after discontinuation (396 patients).

ESMO - logo

FDA approves Tucatinib for patients with HER2-positive metastatic breast cancer


On 17 April 2020, the US Food and Drug Administration (FDA) approved (TUKYSA, Seattle Genetics, Inc.) in combination with trastuzumab and capecitabine, for adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting.

ESMO - logo

FDA grants accelerated approval to Pemigatinib for cholangiocarcinoma with an FGFR2 rearrangement or fusion


On 17 April 2020, the US Food and Drug Administration (FDA) granted accelerated approval to pemigatinib (PEMAZYRE, Incyte Corporation) for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test.

ESMO - logo

FDA approves Mitomycin for low grade upper tract urothelial cancer


On 15 April 2020, the US Food and Drug Administration (FDA) approved Mitomycin for adult patients with low grade upper tract urothelial cancer. Efficacy determination was based on OLYMPUS (NCT02793128), an ongoing, single-arm, multicentre trial enrolling 71 patients.

Rak jelita grubego – aktualne dylematy i problemy w leczeniu - baner

Webinar: Rak jelita grubego – aktualne dylematy i problemy w leczeniu


PZWL Wydawnictwo Lekarskie zaprasza 28 kwietnia (wtorek) o godzinie 18:00 do udziału w bezpłatnym webinarium. Podczas spotkania prof. Lucjan Wyrwicz omówi aktualne dylematy i problemy w leczeniu pacjentów chorych na raka jelita grubego i odpowie na Państwa pytania w tym zakresie.

ESMO - logo

Cancer Core Europe Urges To Close Key Knowledge Gaps on COVID-19 in Cancer Patients


Scientific evidence is lacking in many domains as COVID-19 is a novel disease. Such situation prompted decision making processes in healthcare based on expert opinion. An article published on 16 April 2020 in the Nature Medicine features how seven comprehensive cancer centres within Cancer Core Europe have reorganised in a short time as a response to COVID-19 pandemic.

ASCO - logo

Utilizing Neoadjuvant Immunotherapy Combination in Triple-Negative Breast Cancer


Triple-negative breast cancer (TNBC) accounts for approximately 15% of all breast cancer and is often aggressive with worse outcomes compared with other breast cancer subtypes. TNBC exhibits the strongest immunogenicity among all breast cancer subtypes1 and serves as the ideal testing ground for immune modulation in an attempt to improve survival outcomes.

ESMO - logo

Protecting Medical Staff to Ensure Cancer Patients Can Safely Receive Care During the Pandemic


As the proportion of healthcare workers with COVID-19 has rapidly increased in many countries since the beginning of the outbreak, implementing efficient measures to protect medical teams has become a top priority globally, with clear benefits for the quality of care in oncology too. With Antonio Passaro, European Institute of Oncology (IEO), Milan, Italy

NCCN - logo

Managing of Prostate Cancer During the COVID-19 Pandemic


During the COVID-19 global pandemic,cancer patients and physicians must carefully weigh the potential benefit of routine cancer care versus the high morbidity and mortality of COVID-19, especially in patients of older age, patients with comorbidities, and those with cancer.

Rekomendacje diagnostyczno-terapeutyczne u chorych na czerniaki - baner

Rekomendacje diagnostyczno-terapeutyczne u chorych na czerniaki


Via Medica zaprasza do udziału w Virtual Meeting: Rekomendacje diagnostyczno-terapeutyczne u chorych na czerniaki w sytuacji ograniczonych zasobów i restrykcji związanych z pandemią SARS-CoV-2. Webinar odbędzie się we wtorek 7 kwietnia, w godzinach 18.00-20.00. Więcej informacji na stronie

ASCO - logo

ASCO Coronavirus Resources


As the coronavirus (COVID-19) continues to spread, American Society of Clinical Oncology is committed to providing the most current information and resources to its members and the larger oncology community to help ensure that individuals with cancer receive high-quality care. ASCO has compiled a wide range of resources to support clinicians, the cancer care delivery team, and patients with cancer. This is a rapidly evolving situation and ASCO resources will be updated on a regular basis.

European School of Oncology - logo

COVID-19 - Impact in oncology


Polskie Towarzystwo Chirurgii Onkologicznej poleca uwadze polskich onkologów, w tym chirurgów onkologicznych, przygotowane przez European School of Oncology kompendium wiedzy w formie rekomendacji oraz e-wykładów dotyczących postępowania z chorymi na nowotwory w dobie pandemii COVID-19.

Podręcznik prewencji i leczenia COVID-19 - okładka

Podręcznik prewencji i leczenia COVID-19


Dzięki inicjatywie studentów z Uniwersytetu Medycznego w Poznaniu została przetłumaczona na język polski publikacja „Handbook of COVID-19 Prevention and Treatment”, opracowana przez naukowców z Chin. Pod podanym poniżej linkiem można pobrać najbardziej aktualną wersję tłumaczenia.

baner akcji Grupy PWN - Zostań w domu z nauką

Zostań w domu z nauką i PWN. Wsparcie pracy zdalnej środowiska naukowego


Pandemia COVID-19 diametralnie zmieniła naszą rzeczywistość. Przyszło nam się mierzyć z wyzwaniami, na które nikt nie był przygotowany. Rewolucja nie ominęła świata nauki. Z dnia na dzień funkcjonowanie uniwersytetów i instytucji badawczych przeniosło się do przestrzeni wirtualnej. Środowisko akademickie, naukowe straciło swobodę dostępu do zasobów bibliotecznych, laboratoriów, sal wykładowych.

ASBS - logo

Recommendations for Prioritization, Treatment and Triage of Breast Cancer Patients During the COVID-19 Pandemic: Executive Summary


The COVID-19 pandemic poses unprecedented challenges for patients, clinicians and health care systems. We assembled representatives from multiple cancer care organizations with expertise in the multidisciplinary management of breast disease to provide preliminary recommendations for the triage and treatment of patients with breast disease amidst the COVID-19 pandemic. These are recommendations, and are not intended to supersede individual physician judgement, nor institutional policy or guidelines.

ESMO - logo

Findings from a Retrospective Case Study of COVID-19 Infection in Cancer Patients in Wuhan: An Emphasis on Severe Events


A study team composed from clinicians from three hospitals in Wuhan, China, led by Dr Min Zhou of the Department of the Respiratory and Critical Care Medicine, Tongji Hospital, performed a retrospective case study of clinical features among 28 patients with cancer and COVID-19 infection. In particular, they analyzed the risk factors associated with admission to an intensive care unit, the use of mechanical ventilation or death. Their series was associated with poor outcomes. There was increased risk of developing severe events, especially if the last antitumour treatment was within 14 days of COVID-19 diagnosis.


Leczenie systemowe pacjentów z rozpoznaniem choroby nowotworowej w kontekście pandemii SARS-CoV-2 — stanowisko Polskiego Towarzystwa Onkologii Klinicznej


Do powszechnej wiedzy należy już fakt, że populacją najbardziej narażoną na powikłania i śmierć w wyniku zarażenia SARS-CoV-2 są osoby w podeszłym wieku z chorobami współistniejącymi. Ponieważ większość (> 60%) przypadków nowotworów rozpoznaje się po 65. roku życia, a w Polsce obecnie żyje około miliona osób z rozpoznaniem choroby nowotworowej (w tym duża grupa jest w trakcie aktywnego leczenia), nie ulega wątpliwości, że jest to populacja szczególnego ryzyka.

koronawirus SARS-CoV-2

The Blind Leading the Blind: COVID-19, Cancer, and the Need for More Data


People with compromised immune systems and/or major medical problems, including patients with active cancer and cancer survivors, are at an increased risk for hospitalization and death from COVID-19. More than 30 cancer centers and other organizations have joined to collaborate on the CCC19 Registry, a survey tool allowing health care professionals to report patients whom they are treating for cancer and also have or are presumed to have COVID-19.

ASCO - logo

Investigators Explore Past Coronavirus Experiences to Help Inform Care During COVID-19 Pandemic


Study investigated the features of oncology patients with confirmed Middle East respiratory syndrome (MERS) at the Ministry of National Guard Health Affairs-Riyadh during the outbreak of June 2015 to determine the clinical course and outcome of affected patients.

ASCO - logo

Treating HR-/HER2-Positive Metastatic Breast Cancer in 2020


The treatment of HR-positive/HER2-positive MBC is an evolving field. Our multicenter, retrospective cohort analysis of more than 6,000 records of patients with HR-positive/HER2-positive stage IV breast cancer suggests that hormonal therapy is the more common care path used in first-line treatment. Furthermore, when combined with anti-HER2 therapy, this regimen may provide the best survival outcomes.

ASCO - logo

Exploring the Role of Adjuvant Postoperative Radiotherapy in Breast Cancer Treatment


Adjuvant radiotherapy is typically delivered to patients with breast cancer with the goal of decreasing local-regional recurrence, which translates to a long-term survival benefit in appropriately selected patients. For node-negative breast cancer with higher T stages and breast cancer with one to three nodal metastases, the addition of regional nodal radiation has been more recently associated with not only a local-regional control benefit but also an equal (if not greater) disease-free survival benefit.

ASCO - logo

The Treatment of Patients With Cancer and Containment of COVID-19: Experiences From Italy


Very limited data are available for patients with cancer during COVID-19 epidemics. In a retrospective analysis including 1,572 COVID-19 cases, authors identified 18 patients with cancer. Patients with cancer were observed to have a higher risk of severe events (a composite endpoint defined as the percentage of patients being admitted to the ICU requiring invasive ventilation, or death) compared with patients without cancer. Moreover, patients who underwent chemotherapy or surgery in the past month had a numerically higher risk of clinically severe events than did those not receiving chemotherapy or surgery.

NCCN - logo

How to Manage Cancer Care during COVID-19 Pandemic


Experts from the Seattle Cancer Care Alliance (SCCA) - a Member Institution of the National Comprehensive Cancer Network - are sharing insights and advice on how to continue providing optimal cancer care during the novel coronavirus (COVID-19) pandemic.

koronawirus SARS-CoV-2

COVID-19 infekcja wywołana koronawirusem SARS-CoV-2


W związku z epidemią zakażeń koronawirusem SARS-CoV-2 i szczególnym zagrożeniem dla osób ze współistniejącymi chorobami przewlekłymi, z obniżoną odpornością oraz osób starszych zamieszczamy materiał informacyjny dotyczący COVID-19.

ASCO - logo

ASCO Releases Resource-Stratified Guideline on the Treatment of Late-Stage Colorectal Cancer


ASCO has released a new guideline for clinicians and policymakers in resource-constrained settings on treating patients with late-stage colorectal cancer. The guideline Expert Panel took into account previously published guidelines from around the world including guidelines from the National Comprehensive Cancer Network, European Society for Medical Oncology, The United Kingdom’s National Institute for Health and Care Excellence and more.

ESMO - logo

Use of Both, MRI-Targeted and 12-Core Systematic Biopsies in Prostate Cancer


In a study that involved 2013 men with elevated prostate specific antigen, the use of both, magnetic resonance imaging (MRI)-targeted and 12-core systematic biopsies was more effective at detecting clinically significant prostate cancers than either biopsy method alone. The results are published on 5 March 2020 in The New England Journal of Medicine.

immunotarapia - ilustracja poglądowa

What’s Next in Immunotherapy for Pancreatic Cancer? New Immune Cell Type May Be Key


Current immunotherapies don’t work for most people with cancer. Researchers have identified an overlooked immune cell type that may react to targeted therapies to rally a more powerful immune response in more cancer patients.

baner konferencji „Standardy i nowości w onkologii spersonalizowanej i interdyscyplinarnej”

Konferencja „Standardy i nowości w onkologii spersonalizowanej i interdyscyplinarnej”


Tym razem szczególny nacisk zostanie położony na standardy i nowości w onkologii interdyscyplinarnej i spersonalizowanej. Chcemy Państwu zaprezentować nowoczesną, a więc interdyscyplinarną onkologię, czyli łączącą w walce o wspólny cel przedstawicieli różnych specjalizacji.

esmo logo

EORTC Updates QoL Module in Breast Cancer


A group of researchers published in the February 2020 issue of the Annals of Oncology about process of updating and testing of the European Organization for Research and Treatment of Cancer (EORTC) questionnaire to assess quality of life (QoL) in breast cancer patients. The final updated module contains a total of 45 items from which 22 are new.

BIDMC logo

Platinum-based Agents are Not Superior to Standard Chemotherapy for Patients with Breast Cancer Who Carry BRCA Mutations


Led by clinician-researchers at Beth Israel Deaconess Medical Center (BIDMC), a first-of-its-kind study provided new evidence about the optimal way to treat patients who carry BRCA mutations – also known as BRCA carriers – who have been diagnosed with breast cancer. The new data come from the INFORM trial, the results of which appeared in the Journal of Clinical Oncology.

baner konferencji Akademia Raka Piersi 2020

5. Edycja Akademii Raka Piersi


Polskie Towarzystwo Chirurgii Onkologicznej i PZWL zapraszają do udziału w kolejnej edycji Akademii Raka Piersi. Podczas konferencji zostaną przedstawione aktualne zasady leczenia w formie algorytmów sporządzonych osobno dla chorych z rakami luminalnymi, HER2-dodatnimi i trójujemnymi. Będą one omawiane przez wielodyscyplinarny zespół specjalistów – złożony z chirurga, onkologa klinicznego i radioterapeuty – zgodnie z chronologią leczenia.

esmo logo

EMA Started a Review of Trabectedin


European Medicines Agency (EMA) announced on 28 February 2020 that its Committee for Medicinal Products for Human Use (CHMP) has started a review of trabectedin (Yondelis), the cancer medicine used to treat ovarian cancer and soft-tissue sarcoma. The review started after a clinical study OVC-3006, which investigated the use of Yondelis in patients with ovarian cancer, was stopped ahead of time.

esmo logo

EMA Recommends Extension of Therapeutic Indications for Brigatinib


On 27 February 2020, the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product brigatinib (Alunbrig). Alunbrig is indicated as monotherapy for the treatment of adult patients with ALK positive advanced non-small cell lung cancer (NSCLC) previously not treated with an ALK inhibitor.

ESMO - logo

FDA Approves Neratinib in Combination with Capecitabine for Metastatic HER2-positive Breast Cancer


On 25 February 2020, the US Food and Drug Administration (FDA) approved neratinib (NERLYNX, Puma Biotechnology, Inc.) in combination with capecitabine for management of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 based regimens in the metastatic setting.

ASCO - logo

Current and Future Applications of Circulating-Tumor DNA in Lung Cancer


The recent advent of cell-free DNA (cfDNA) or circulating-tumor DNA (ctDNA) platforms to genotype lung cancer has drastically altered the diagnostic paradigm in NSCLC. These platforms have a number of advantages: They are minimally invasive, have a rapid turnaround time, and can be performed serially. In addition, molecular alterations identified in ctDNA seem to be as predictive of response to targeted therapies as those identified in tissue.

baner konferencji Akademia Onkologii Urologicznej 2020

Akademia Onkologii Urologicznej 2020


Zapraszamy do udziału w Akademii Onkologii Urologicznej, której celem jest przybliżenie postępów i omówienie standardów postępowania z pacjentem chorym na nowotwory wywodzące się z układu moczowego i płciowego mężczyzny – z perspektywy urologa, onkologa i radioterapeuty.

ECOG-ACRIN Cancer Research Group - logo

Abbreviated MRI outperforms 3D mammograms at finding cancer in dense breasts


According to a study published today in the Journal of the American Medical Association (JAMA), abbreviated breast magnetic resonance imaging (MRI) detected significantly more cancers than digital breast tomosynthesis (3-D mammography) in average-risk women with dense breast tissue.

esmo logo

Largest Real World Dataset of Immune Checkpoint Inhibitors in Melanoma Treatment Demonstrates Similar Outcomes to Randomised Clinical Trials


Findings from a largest real world dataset in metastatic melanoma setting demonstrate rapid uptake of immune checkpoint inhibitors and patient outcomes similar to those achieved in randomised clinical trials. Use of emergency services varied by regimen, with colitis dominating hospitalisation after treatment with ipilimumab or ipilimumab plus nivolumab treatment. The results were presented at 2020 ASCO-SITC Clinical Immuno-Oncology Symposium.

esmo logo

Real-World Data Validation of Association Between Immunoregulatory Molecules Expression and Targetable Cancer Genes


There may be a role for combining targets identified by next-generation sequencing along with patterns of immunoregulatory molecules expression to better guide future design of clinical trials in various cancer types in a tissue-agnostic fashion according to an independent, validated real-world dataset of immunoregulatory molecules in the presence of certain gene mutations. The findings were presented during the 2020 ASCO-SITC Clinical Immuno-Oncology Symposium.

immunotherapy - illustration

Predicting immunotherapy success


One of the frustrations with anti-cancer therapy is that no one drug fits all: Most work well in some people but have little effect in other patients with the same type of cancer. This is as true of the newer immunotherapy treatments as it is of older types of chemotherapy. Weizmann Institute of Science researchers have now identified new markers that can help predict which patients have a better chance for a positive response to immunotherapy treatments. Their findings were reported in Nature Communications.

esmo logo

WHO Estimation of Cervical Cancer Mortality


Findings from a comparative modelling analysis in 78 low-income and lower-middle-income countries (LMICs) performed by the World Health Organization (WHO) Cervical Cancer Elimination Modelling Consortium emphasise the importance of acting immediately on three fronts to scale up human papillomavirus (HPV) vaccination, screening, and treatment for pre-invasive and invasive cervical cancer.

Yale Cancer Center logo

Study shows long-term survival benefit for certain patients with advanced lung cancer


According to the results of a large, global study led by Yale Cancer Center researchers, even a tiny amount of a biomarker known as PD-L1 (programmed death-ligand1) can predict a long-term survival benefit from using pembrolizumab (Keytruda). The drug is one of the first checkpoint inhibitors to be developed and used in cancer treatment. The findings are published online today in the Journal of Clinical Oncology.

asco logo

First-Line Treatment of Patients With Advanced NSCLC and High PD-L1 Expression: Immunotherapy With or Without Chemotherapy?


Currently, whether to treat patients with advanced non–small cell lung cancer (NSCLC) and high PD-L1 expression with first-line immunotherapy with or without chemotherapy (platinum doublet) is based on clinician discretion, as both are considered standards of care. There are no currently published randomized clinical trials comparing these treatment options.

esmo logo

Talazoparib Shows Encouraging Antitumour Activity in Docetaxel Pretreated mCRPC


On behalf of TALAPRO-1 investigators, Prof. Johann de Bono presented at 2020 Genitourinary Cancers Symposium the results of first interim analysis of the phase II trial with PARP inhibitor talazoparib performed among patients with DNA damage repair (DDR) mutations and docetaxel pretreated metastatic castration-resistant prostate cancer (mCRPC). The study team found that monotherapy with talazoparib demonstrated encouraging antitumour activity in this population, especially in patients with BRCA1/2 mutations. The treatment was well tolerated.

asco logo

Neoadjuvant Chemo-Immunotherapy Yields Good Pathologic Response Rates in Muscle-Invasive Bladder Cancer


The combination of nivolumab with gemcitabine and cisplatin in the neoadjuvant setting was well tolerated and resulted in promising pathologic response rates in patients with muscle-invasive bladder cancer (MIBC), according to results of the phase II BLASST-1 study.

asco logo

HIF-2ɑ Inhibitor, Novel TKI Show Some Progress in Early Advanced RCC


Two novel agents have shown promise in early-phase trials of patients with advanced clear cell renal cell carcinoma (ccRCC). One agent, sitravatinib, is a multitargeted tyrosine-kinase inhibitor (TKI) administered in combination with nivolumab, while the other, known as MK-6482, is an inhibitor of HIF-2ɑ given as monotherapy.

esmo logo

Cervical Cancer Elimination in Low-Income and Lower-Middle-Income Countries


A comparative modelling analysis in 78 low-income and lower-middle-income countries (LMICs) suggest that high human papillomavirus (HPV) vaccination coverage of girls can lead to cervical cancer elimination in most LMICs by the end of the century. Screening with high uptake will expedite reductions and will be necessary to eliminate cervical cancer in countries with the highest burden. The findings are published online on 30 January 2020 in The Lancet.

kidney cancer

Cutting off kidney cancer at its roots


Scientists at the Max Delbrück Centrum for Molecular Medicine (MDC) have discovered stem cells responsible for the most common form of kidney cancer. The team of Walter Birchmeier has found a way to block the growth of these tumors in three models of the disease.

asco logo

Antibiotic Exposure Worsens Survival and Colitis in Patients With Stage III and IV Melanoma Receiving ICIs


Patients with stage III and stage IV melanoma receiving immune checkpoint inhibitors (ICIs) had decreased overall survival (OS) and increased melanoma-specific mortality and risk for moderate to severe colitis if they were treated with antibiotics, according to a large retrospective study presented during the 2020 ASCO-SITC Clinical Immuno-Oncology Symposium.

esmo logo

Colorectal Cancer in Ulcerative Colitis and Crohn’s Disease


According to a Scandinavian population-based cohort study, individuals with ulcerative colitis (UC) are at increased risk of developing colorectal cancer (CRC) compared with those without UC, are diagnosed with less advanced CRC, and are at increased risk of dying from CRC, although these excess risks have declined substantially over time. Furthermore, patients with Crohn's disease are at increased risk of diagnosis and death from CRC. Patients with Crohn's disease who have CRC have a higher mortality than patients without Crohn's disease who are also diagnosed with CRC.

ASCO logo

Urine-Based RNA Assays Show Promise for Diagnosis, Classification of Prostate Cancer


Analysis of small non-coding RNA (sncRNA) from a single urine sample could offer a simple and accurate way to diagnose prostate cancer and differentiate between low- and high-grade, high-risk forms of the malignancy, according to a new study.

esmo logo

HPV Vaccine Hesitancy


Although the human papillomavirus (HPV) vaccine is still included in the Japanese national immunisation programme and is provided free of charge for girls aged 12–16 years, the Japanese Government suspended proactive recommendations for the vaccine in June 2013, after unconfirmed reports of adverse events following immunisation appeared in the media. Vaccine coverage declined rapidly from more than 70% to less than 1%. It is estimated that the HPV vaccine crisis result to date in around 5000 deaths from cervical cancer in Japan.

ASCO logo

Vitamin D Intake May Reduce Risk of Immune Checkpoint Inhibitor–Induced Colitis


Patients who were taking vitamin D supplements when initiating immune checkpoint inhibitor (ICI) therapy had significantly reduced odds of developing ICI–related colitis, according to a retrospective study (Abstract 89) presented during the 2020 ASCO-SITC Clinical Immuno-Oncology Symposium.

endometrial cancer histologic view

Study Surveys Molecular Landscape of Endometrial Cancer


The most comprehensive molecular study of endometrial cancer to date has further defined the contributions of key genes and proteins to the disease, say its authors. Published online February 13 in Cell, the study suggests new treatment approaches that could be tailored for each patient, as well as potential biological targets for future drug design.

esmo logo

Treatment of Helicobacter Pylori Infection May Reduce the Risk of Gastric Cancer


Findings from a study performed in South Korea among persons with Helicobacter pylori infection who had a family history of gastric cancer in first-degree relatives, show that Helicobacter pylori eradication treatment reduced the risk of gastric cancer. The results from this randomised trial are published on 30 January 2020 in The New England Journal of Medicine.

esmo logo

The Role of Adjuvant Radiotherapy in Improving Outcomes for Locally Advanced Bladder Cancer


Adjuvant RT significantly improves local control and suggest that this improvement in local control may translate to a benefit in survival for patients with bladder cancer. Patients with locally advanced bladder cancer at the time of radical cystectomy have an estimated 5-year overall survival (OS) of only 10% to 40%.1 Approximately one-third will develop a local-regional recurrence at the initial site of failure after surgery, and distant metastases are common.1-3 Adjuvant chemotherapy is frequently employed for patients with locally advanced bladder cancer who did not receive neoadjuvant chemotherapy to address the risk of distant disease.

esmo logo

Treatment with CAR-NK Cells in Patients with Relapsed or Refractory CD19-positive Lymphoid Tumours


Among 11 patients with relapsed or refractory CD19-positive lymphoid tumours, a majority had a response to treatment with chimeric antigen receptor (CAR) natural killer (NK) cells without the development of major toxic effects. Allogeneic CAR-NK cells can be delivered in adoptive transfer without the serious cytokine release syndrome and neurologic toxic effects according to study findings published online on 6 February 2020 in The New England Journal of Medicine.

esmo logo

EMA Recommends Granting a Marketing Authorisation for Biosimilar Rituximab


On 30 January 2020, the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Ruxience (rituximab), intended for the treatment of non-Hodgkin’s lymphoma (NHL), chronic lymphocytic leukaemia (CLL), rheumatoid arthritis (RA), granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), and Pemphigus vulgaris (PV).

baner panelu dyskusyjnego Mammotome na konferencji Falenty 2020

Panel dyskusyjny „Sposób postępowania ze zmianami ogniskowymi u pacjentek z grupy wysokiego ryzyka”


26 marca w ramach konferencji „Przyszłość leczenia i pielęgnacji chorych na raka piersi w Polsce. Falenty 2020” odbędzie się panel dyskusyjny „Sposób postępowania ze zmianami ogniskowymi u pacjentek z grupy wysokiego ryzyka – dyskusja przypadków”.

okładka podręcznika „Onkologia” wydawnictwa AsteriaMed

„Onkologia” nowy podręcznik wydawnictwa AsteriaMed


Nakładem wydawnictwa AsteriaMed ukazała się nowa pozycja o tematyce onkologicznej, uwzględniająca najnowszy i aktualny stan wiedzy, zatytułowana „Onkologia. Podręcznik dla studentów medycyny. Pomoc dydaktyczna dla lekarzy specjalizujących się w onkologii”.

baner konferencji Akademia Raka Jelita Grubego

Akademia Raka Jelita Grubego 2020


Ruszyła 2. edycja Akademii Raka Jelita Grubego – cyklu konferencji skierowanych do lekarzy wszystkich specjalizacji zaangażowanych w leczenie chorych na raka jelita grubego.

baner konferencji Przyszłość leczenia i pielęgnacji chorych na raka piersi w Polsce „Falenty 2020”

Konferencja Przyszłość leczenia i pielęgnacji chorych na raka piersi w Polsce „Falenty 2020”


W imieniu organizatorów zapraszamy na XIV Międzynarodową Konferencję Przyszłość leczenia i pielęgnacji chorych na raka piersi w Polsce „Falenty 2020” organizowaną przez Polskie Towarzystwo do Badań nad Rakiem Piersi. Konferencja odbędzie się w Warszawie 26-28 marca 2020 roku.

baner konferencji Postępy w Ginekologii Onkologicznej

XXV Konferencja Naukowa Postępy w Ginekologii Onkologicznej


W imieniu profesora Zbigniewa Kojsa – Konsultanta Krajowego w Dziedzinie Ginekologii Onkologicznej oraz Organizatorów zapraszamy do udziału w Konferencji Naukowej „Postępy w Ginekologii Onkologicznej”. Celem Konferencji jest doskonalenie wiedzy onkologicznej wśród lekarzy ginekologów. Odbędzie się ona 10-11 września 2020 r. w Hotelu Mercure Kasprowy w Zakopanem.

baner konferencji Akademia Czerniaka

Ruszyła 7. edycja konferencji Akademia Czerniaka


Akademia Czerniaka to wydarzenia, które od wielu lat wyróżniają się na polskiej mapie konferencji medycznych interdyscyplinarnym programem skierowanym zarówno do chirurgów onkologicznych, onkologów, dermatologów, ale również do radioterapeutów i patologów.

Marker chirurgiczny HydroMARK wspomagający leczenie oszczędzające w raku piersi

Marker chirurgiczny wspomagający leczenie oszczędzające w raku piersi


Współczesne leczenie raka piersi ukierunkowane jest na zachowanie piersi. Obecnie, również w sytuacjach, gdzie dotychczas nie było możliwe wykonanie zabiegów oszczędzających, można uzyskać warunki do ich przeprowadzenia.

baner konferencji „Rak jelita grubego - ewolucja standardów i nowe możliwości diagnostyki i leczenia”

Konferencja „Rak jelita grubego - ewolucja standardów i nowe możliwości diagnostyki i leczenia”


Podyskutujmy o endoskopii, nauczmy się oceniać na własne potrzeby badania obrazowe, zobaczmy na żywo, jak operuje się raka okrężnicy, a jak raka odbytnicy. Posłuchajmy, co ma do powiedzenia patomorfolog. Skonfrontujmy oczekiwania chirurgów, onkologów klinicznych i radioterapeutów.

Warmińsko-Mazurskie Warsztaty Onkologiczne 2019 - baner

„Dylematy w onkologii” - XI Warmińsko-Mazurskie Warsztaty Onkologiczne


Już po raz jedenasty w dniach 25 - 26 października 2019 roku odbędą się Warmińsko-Mazurskie Warsztaty Onkologiczne. Celem warsztatów prowadzonych przez znakomitych wykładowców, lekarzy praktyków jest zwrócenie uwagi na istotne klinicznie zagadnienia.

Agencja Badań Medycznych - logo

Konferencja „Cancer Prevention 2020”


Problem zachorowań na nowotwory złośliwe jest jednym z najważniejszych wyzwań zdrowotnych przed którym stoi dziś polski system ochrony zdrowia. Konferencja inicjowana przez Agencję Badań Medycznych prowadzić ma do dyskusji na temat udoskonalenia obecnego systemu i jego poprawy w zakresie praktyk klinicznych i badawczych.

Patologia Domagały tom II - okładka

Stachury i Domagały Patologia znaczy słowo o chorobie


Właśnie ruszyła sprzedaż drugiego tomu (wydanie trzecie zmienione i poprawione) Stachury i Domagały Patologii, czyli słowa o chorobie, wydanego przez Wydawnictwo Polskiej Akademii Umiejętności. Omówiono w nim m. in. najnowsze klasyfikacje histologiczne nowotworów.

Akademia Onkologii Urologicznej 2019 - baner

Akademia Onkologii Urologicznej 2019 - cykl spotkań warsztatowych


W imieniu PZWL Wydawnictwa Lekarskiego i prof. Pawła Wiechno serdecznie zapraszamy lekarzy onkologów, chirurgów, radioterapeutów, urologów i immunologów do udziału w warsztatach z cyklu Akademia Onkologii Urologicznej, które odbędą się jesienią 2019 r.

Akademia Raka Płuca edycja 2019 - baner

Akademia Raka Płuca 2019 - cykl spotkań warsztatowych


Jakie są najbardziej aktualne tematy dotyczące diagnostyki, profilaktyki i leczenia chorych na raka płuc? Jak rysuje się przyszłość terapii ukierunkowanych molekularnie? Jakie są najnowsze osiągnięcia w chemioterapii? Te i inne zagadnienia poruszone zostaną podczas bezpłatnych spotkań warsztatowych „Akademia Raka Płuca”.

Debaty Rak prostaty - baner

Debaty Rak prostaty


8 czerwca odbędą się w Warszawie Debaty Rak prostaty, na które serdecznie zapraszamy. Tematyka obejmie zagadnienia związane z biopsją prostaty, neuro mapping, leczenie rozsianego raka stercza oraz seks z rakiem stercza.

V Seminarium UroRadioOnkologii - edycja 2019 - baner

V Seminarium UroRadioOnkologii


18 maja odbędzie się V Seminarium UroRadioOnkologii. Obejmie ono wykłady, dyskusje eksperckie oraz debaty, między innymi o terapii BCG, terapii systemowej, leczeniu raka stercza czy aktualnych standardach leczenia rozsianego rak nerki w Polsce.

„Rak Płuca w Centrum” baner konferencji

„Rak Płuca w Centrum” - konferencja poświęcona problematyce leczenia raka płuc


W dniach 12 i 13 kwietnia w Łodzi odbędzie się I Konferencja „Rak Płuca w Centrum”. Celem Konferencji jest wzrost świadomości na temat nowoczesnych metod diagnostyki i leczenia raka płuca, jak również usprawnienie organizacji pracy w tym zakresie.

Innowacyjne terapie w onkologii - edycja 2019 - baner konferencji

Konferencja „Innowacyjne terapie w onkologii” 2019


Jakie zmiany nastąpiły ostatnio w prowadzeniu nowoczesnych terapii onkologicznych? Jak można wykorzystać mechanizmy naprawy DNA jako potencjalne cele leków przeciwnowotworowych? Te i inne zagadnienia poruszone zostaną przez wybitnych ekspertów podczas konferencji Warszawskiego Oddziału Polskiego Towarzystwa Onkologicznego.

Akademia Raka Jelita Grubego edycja 2019 - baner konferencji

Akademia Raka Jelita Grubego - cykl konferencji naukowych


PZWL Wydawnictwo Lekarskie wraz z Kierownikiem Naukowym prof. nadzw. dr hab. n. med. Lucjanem Wyrwiczem zaprasza na cykl konferencji naukowych Akademia Raka Jelita Grubego. Swoją wiedzą i doświadczeniami w zakresie diagnostyki oraz leczenia raka jelita grubego podzielą się wybitni specjaliści z całego kraju.

Akademia Raka Piersi edycja 2019 - baner konferencji

Akademia Raka Piersi 2019 - w tym roku nowa formuła konferencji


Klinika Nowotworów Piersi i Chirurgii Rekonstrukcyjnej Centrum Onkologii w Warszawie i PZWL Wydawnictwo Lekarskie zapraszają na kolejną edycję konferencji z cyklu Akademia Raka Piersi 2019.

baner konferencji onkologicznej „Kontrowersje w onkologii”

6 edycja ogólnopolskiej konferencji onkologicznej „Kontrowersje w onkologii”


Zbliża się już 6 edycja Ogólnopolskiej konferencji onkologicznej „Kontrowersje w onkologii” pod kierownictwem prof. Piotra Potemskiego. Poniżej przedstawiamy program konferencji, a więcej szczegółów znajdziecie Państwo na stronie organizatora konferencji.

Akademia Czerniaka edycja 2019 - baner konferencji

Akademia Czerniaka 2019 – VI edycja cyklu konferencji naukowych


Polskie Towarzystwo Chirurgii Onkologicznej oraz PZWL Wydawnictwo Lekarskie zapraszają na VI edycję cyklu poświęconego tematyce czerniaka. Spotkania, którym przewodniczy prof. Piotr Rutkowski, przeznaczone są dla wszystkich zainteresowanych lekarzy, a w szczególności chirurgów, onkologów klinicznych i dermatologów.

Obserwuj Onkonet na Facebooku

Preparat Nutridrink do leczenia żywieniowego firmy Nutricia

preparat do leczenia żywieniowego Nutridrink firmy Nutricia